NEW YORK, NEW YORK – The U.S. Chamber of Commerce and the U.S. Department of State hosted the first public discussion about the State Department's new global health strategy at an event on the sidelines of the 80th United Nations General Assembly. “The Future of U.S. Global Health Diplomacy and Assistance” event yesterday featured leaders in government and business to discuss the intersection of U.S. global health strategy with national security and commercial interests.
“As the voice of American business, the Chamber has long championed the critical role of the private sector in strengthening health systems worldwide,” said Varnee Murungan, Executive Director of the Chamber’s Global Initiative on Health and the Economy. "At the Chamber, we continue to identify and advocate for market-based solutions that improve health outcomes around the world.”
“Collaboration with the private sector is key to promoting American health innovations, saving lives around the world, and making America safer,” said State Department Senior Bureau Official for Global Health Security and Diplomacy Jeff Graham. “The America First Global Health Strategy is leading the way on creating more durable and resilient local health systems.”
Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences, added, “Lenacapavir for HIV prevention exemplifies how we can deploy U.S. innovation through U.S. State Department assistance to improve global public health and, in this case, help to end HIV. Through continued partnerships, we can ensure sustainable solutions that generate greater health and prosperity for the U.S and for the countries with the greatest need."
"Our investments in American diagnostics innovation serve a dual purpose: they are instrumental in advancing US global health goals like ending mother-to-child HIV transmission in high burden countries and are now a key component in building resilient health systems across Africa," said Joanna Sickler, Vice-President for Health Policy & External Affairs at Roche Diagnostics.
“Expanding access to healthcare takes collaboration, and the new U.S. global health strategy highlights the essential role of public-private partnerships,” said Tim Hogan, Senior Vice President, Global Policy & Public Affairs at Pfizer. “Through our first-of-its-kind Accord for a Healthier World initiative, we are working with governments in lower-income countries to improve access to medicines and vaccines while also helping to build health system capacity to enable locally led, sustainable solutions.”
